Karen Bush – författare

This is the inaugural volume in a new series of reviews. Each annual volume will contain authoritative reviews of developing research topics in antimicrobial therapeutics.  Authors will describe how the research being reviewed can be applied to real-world problems.  Among the topics discussed are:  antibiotic cycling (rotation) to reduce emergence of resistance; antibiotics: past and future medical need and public perception; drug discovery successes and failures; efflux pumps and the possibility for broad-spectrum inhibitors; emergence of Clostridium difficile as a major nosocomial pathogen; immunomodulators as adjuvants for antimicrobial therapy and vaccines; potential impact of rapid diagnostics to direct more targeted therapies, or to affect antimicrobial use; regulatory hurdles for new antibiotics; the interface between veterinary and human antibiotic use; and virtual high throughput screening and structure-based design of anti-bacterials. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

This second installment of Antimicrobial Therapeutics Reviews presents scholarly reviews on several key areas in the field of antimicrobial therapeutics, including several papers on issues relating to antibiotics that target the ribosome.  Topics covered include plasmid-encoded resistance determinants for agents that bind the ribosome, new compound classes targeting the ribosome, sequence-specific action of antibiotics binding the ribosome, smFRET approaches to determine MOA of antibiotics binding to the ribosome, new approaches for treating Staphylococcus biofilm infections, and the history of tetracyclins.  The volume also features reviews dealing with drug development, such as pleuromutilin discovery and development challenges and an update on newer oxazolidinones such as torezolid and radezolid, and a review on regulatory hurdles for new antibiotics. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.